PMC:7172841 / 1919-2076 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T21","span":{"begin":47,"end":60},"obj":"Body_part"}],"attributes":[{"id":"A21","pred":"fma_id","subj":"T21","obj":"http://purl.org/sig/ont/fma/fma264829"}],"text":"nd is defective antigen-presentation driven by interleukin-6. An IL-6 blocker partially rescues immune dysregulation in vitro and in patients.\n\nIntroduction\n"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T19","span":{"begin":47,"end":60},"obj":"http://purl.obolibrary.org/obo/PR_000001393"}],"text":"nd is defective antigen-presentation driven by interleukin-6. An IL-6 blocker partially rescues immune dysregulation in vitro and in patients.\n\nIntroduction\n"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T15","span":{"begin":16,"end":23},"obj":"Chemical"},{"id":"T16","span":{"begin":65,"end":67},"obj":"Chemical"}],"attributes":[{"id":"A15","pred":"chebi_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"},{"id":"A16","pred":"chebi_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A17","pred":"chebi_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"}],"text":"nd is defective antigen-presentation driven by interleukin-6. An IL-6 blocker partially rescues immune dysregulation in vitro and in patients.\n\nIntroduction\n"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T14","span":{"begin":16,"end":36},"obj":"http://purl.obolibrary.org/obo/GO_0019882"}],"text":"nd is defective antigen-presentation driven by interleukin-6. An IL-6 blocker partially rescues immune dysregulation in vitro and in patients.\n\nIntroduction\n"}

{"project":"LitCovid-sentences","denotations":[{"id":"T19","span":{"begin":62,"end":142},"obj":"Sentence"},{"id":"T20","span":{"begin":144,"end":156},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"nd is defective antigen-presentation driven by interleukin-6. An IL-6 blocker partially rescues immune dysregulation in vitro and in patients.\n\nIntroduction\n"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T12","span":{"begin":96,"end":116},"obj":"Phenotype"}],"attributes":[{"id":"A12","pred":"hp_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/HP_0002958"}],"text":"nd is defective antigen-presentation driven by interleukin-6. An IL-6 blocker partially rescues immune dysregulation in vitro and in patients.\n\nIntroduction\n"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T78","span":{"begin":16,"end":23},"obj":"CHEBI:59132;CHEBI:59132"},{"id":"T79","span":{"begin":47,"end":60},"obj":"PR:000001393"},{"id":"T80","span":{"begin":65,"end":69},"obj":"PR:000001393"},{"id":"T81","span":{"begin":96,"end":102},"obj":"UBERON:0002405;GO:0006955"},{"id":"T82","span":{"begin":103,"end":116},"obj":"GO:0006955"}],"text":"nd is defective antigen-presentation driven by interleukin-6. An IL-6 blocker partially rescues immune dysregulation in vitro and in patients.\n\nIntroduction\n"}

{"project":"LitCovid-PubTator","denotations":[{"id":"95","span":{"begin":47,"end":60},"obj":"Gene"},{"id":"96","span":{"begin":65,"end":69},"obj":"Gene"},{"id":"97","span":{"begin":133,"end":141},"obj":"Species"}],"attributes":[{"id":"A95","pred":"tao:has_database_id","subj":"95","obj":"Gene:3569"},{"id":"A96","pred":"tao:has_database_id","subj":"96","obj":"Gene:3569"},{"id":"A97","pred":"tao:has_database_id","subj":"97","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"nd is defective antigen-presentation driven by interleukin-6. An IL-6 blocker partially rescues immune dysregulation in vitro and in patients.\n\nIntroduction\n"}